Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

Michael Vincent, Chief Inflammation & Immunology Officer, Pfizer

“LITFULO has dual selectivity for JAK3 and the TEC family kinases, signals that immune cells use to attack pigment-producing cells in the skin, so it addresses a root cause of nonsegmental vitiligo rather than its visible effects alone. Across the largest Phase 3 program to date evaluating an oral systemic therapy for nonsegmental vitiligo, both TRANQUILLO 2 and TRANQUILLO demonstrated strong and increasing improvements in facial and total body repigmentation over time and also improved patients’ own perception of facial and overall disease severity. We look forward to discussing these results with regulators to bring this potential option to patients as soon as possible.”

Iltefat Hamzavi, Senior Staff Physician, Department of Dermatology, Henry Ford Health and Hamzavi Dermatology Specialists

“Nonsegmental vitiligo is a disease that can have a substantial burden on patients’ lives beyond the visible symptoms on their skin.( 1,2,3) It is a chronic autoimmune disease, yet patients often face stigma because it is trivialized as a condition that affects only skin appearance.( 2) It can progress unpredictably, often across highly visible areas, and for decades people living with vitiligo have relied on limited available treatment options.( 2,3) Research has shown that LITFULO (ritlecitinib) not only significantly improved facial and total body repigmentation, but also resulted in greater disease stabilization compared to the placebo. The results solidify the potential of LITFULO to support a new treatment paradigm rooted in systemic treatment that can address underlying disease drivers for people living with nonsegmental vitiligo.”